[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485446":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":26,"locations":36,"responsibleParty":101,"collaborators":26,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":26,"eligibilityCriteria":109,"healthyVolunteers":105,"sex":110,"minAge":111,"maxAge":26,"enrollmentInfo":112,"targetDuration":26,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":127,"whyStopped":26,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Beker Laboratories","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stadard of care","ACTIVE_COMPARATOR","standard treatment that is prescribed by the treating physician.",[13],"Other: Standard of care",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of care + Respicure®","EXPERIMENTAL","standard treatment that is prescribed by the treating physician in addition to Respicure®",[19],"Other: Respicure®",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"OTHER","Respicure®","Respicure® is an inhalation solution that contains two natural extracts: quercetin and resveratrol in a concentration of 0.38%\u002F0.38%.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard of care","standard treatment is prescribed by the treating physician.",[9],[32],{"name":33,"affiliation":34,"role":35},"Pr Mersak GHARNAOUT, Professor","CHU Beni Messous\u002F Pneumologie A","PRINCIPAL_INVESTIGATOR",[37,48,53,61,69,77,85,93],{"facility":38,"status":26,"city":39,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":26},"CHU Beni Messous\u002FPneumologie A","Algiers","Algeria","DZ",{"type":43,"coordinates":44},"Point",[45,46],3.08746,36.73225,{"lat":46,"lon":45},{"facility":49,"status":26,"city":39,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":50,"geoPoint":52,"contacts":26},"CHU Beni Messous\u002FPneumologie B",{"type":43,"coordinates":51},[45,46],{"lat":46,"lon":45},{"facility":54,"status":26,"city":55,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":56,"geoPoint":60,"contacts":26},"CHU Annaba\u002FPneumo-phtisiologie","Annaba",{"type":43,"coordinates":57},[58,59],7.76667,36.9,{"lat":59,"lon":58},{"facility":62,"status":26,"city":63,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":64,"geoPoint":68,"contacts":26},"EPH Batna\u002FPneumo-phtisiologie","Batna City",{"type":43,"coordinates":65},[66,67],6.17414,35.55597,{"lat":67,"lon":66},{"facility":70,"status":26,"city":71,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":72,"geoPoint":76,"contacts":26},"CHU Constantine\u002FPneumo-phtisiologie","Constantine",{"type":43,"coordinates":73},[74,75],6.61472,36.365,{"lat":75,"lon":74},{"facility":78,"status":26,"city":79,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":80,"geoPoint":84,"contacts":26},"EPH Laghouat\u002FPneumo-phtisiologie","Laghouat",{"type":43,"coordinates":81},[82,83],2.86514,33.8,{"lat":83,"lon":82},{"facility":86,"status":26,"city":87,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":88,"geoPoint":92,"contacts":26},"CHU Oran\u002FPneumo-phtisiologie B","Oran",{"type":43,"coordinates":89},[90,91],-0.63588,35.69906,{"lat":91,"lon":90},{"facility":94,"status":26,"city":95,"state":26,"zip":26,"country":40,"countryCode":41,"cosmosGeoPoint":96,"geoPoint":100,"contacts":26},"CHU Sidi Bel Abbes\u002FPneumo-phtisiologie","Sidi Bel Abbes",{"type":43,"coordinates":97},[98,99],-0.63085,35.18994,{"lat":99,"lon":98},{"type":102,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100485446","evaluation-of-the-efficacy-of-respicure-resveratrol--quercetin-in-the-management-of-respiratory-conditions-including-asthmacopd-and-long-covid-100485446",false,"NCT05601180","Evaluation of the Efficacy of Respicure® (Resveratrol \u002F Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.","Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study Product) Evaluating the Efficacy of Respicure® 0.38% \u002F0.38% (Resveratrol \u002F Quercetin) Phytotherapy Product From BEKER® Laboratories as an add-on Treatment in the Management of Respiratory Conditions Including Asthma (Partially Controlled),Chronic Obstructive Pulmonary Disease \"COPD\" (Stage A, B, C and D) and Long Coronavirus Disease \"COVID\" in Algerian Adult Patients .","* Inclusion Criteria for Asthma patients:\n\n  1. Male, female, aged ≥19.\n  2. Being able to provide written informed consent before the study.\n  3. Patient with partially controlled asthma: Assessment of asthma control over the month preceding the use of Respicure ® by a symptomatic assessment (Tick one or two symptoms):\n\n  3\\. 1 Daytime symptoms more than twice a week, 3. 2 One or more nocturnal awakenings, 3. 3 Need for rescue medication more than twice a week, 3. 4 One or more activity limitations\n\n  4\\. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc…\n* Inclusion Criteria for COPD patients:\n\n  1. Male, female, ≥40 years old\n  2. Being able to provide written informed consent before the study.\n  3. Patient with COPD stage A, B, C or D in stable condition with no exacerbations in the past 4 weeks.\n  4. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc…\n* Inclusion Criteria for long covid patients:\n\n  1. Male, female, aged ≥19.\n  2. Being able to provide written informed consent before the study.\n  3. Patients followed for respiratory symptoms linked to long Covid (symptoms for more than 12 weeks).\n\nExclusion Criteria :\n\n1. Patient with severe asthma (for asthma groupe only)\n2. Prior use of Respicure®.\n3. Concomitant use with the following products: cytochrome P450 3A4 substrate drugs (e.g. statin, antifungals and fexofenadine), antibiotics (quinolones), immunosuppressants (cyclosporine) and glycoprotein P substrate drugs, e.g. antifungal and antiarrhythmic .\n4. Hypersensitivity to any of the ingredients.\n5. Hypersensitivity to peanuts.\n6. Concomitant intake of a product containing one or both of the active ingredients (resveratrol\u002Fquercetine).\n7. Pregnancy\u002F lactation.\n8. People who need to undergo surgery.\n9. Participation in another clinical study within the previous 30 days.\n10. Patient with asthma-COPD overlap syndrome or any other respiratory disease such as pneumonia, tuberculosis, pulmonary embolism, etc.\n11. Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids.\n12. Patients requiring admission to intensive care and\u002For requiring respiratory assistance.\n13. Patients requiring anticoagulant treatment at curative doses.","ALL","19 Years",{"count":113,"type":114},402,"ACTUAL","INTERVENTIONAL",[117],"NA","Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study Product) Evaluating the Efficacy of Respicure® 0.38% \u002F0.38% (Resveratrol \u002F Quercetin) Phytotherapy Product From BEKER Laboratories as an add-on Treatment in the Management of Respiratory Conditions Including Asthma (Partially Controlled),COPD (Stage A, B, C and D) and long COVID in Algerian Adult Patients .",[120,121,122],"Asthma","Chronic Obstructive Pulmonary Disease","Long COVID",[124,125,126],"Phytotherapy","Inhalation","Complementary medicine","COMPLETED","2024-03-18",{"date":130,"type":114},"2024-03-19",{"date":132,"type":114},"2022-10-27",{"date":134,"type":114},"2024-01-15",{"name":5,"class":6},8]